APREPITANT (FOSAPREPITANT)
(Emend, Emend IV)Standard Prescription
aprepitant__mg PO___ on day(s) __ of chemotherapy
fosaprepitant _ mg IV x 1 dose on day 1 of chemotherapy
fosaprepitant _ mg IV x 1 dose on day 1 of chemotherapy
Dosages
Prophylaxis of chemotherapy induced nausea and vomiting (Age > 6 mos)
3 mg/kg/dose (Max 125 mg/dose) PO on day 1 of chemotherapy, then 2 mg/kg/dose (Max 80 mg/dose) PO on days 2 and 3 of chemotherapy
3 mg/kg/dose (Max 125 mg/dose) PO on day 1 of chemotherapy, then 2 mg/kg/dose (Max 80 mg/dose) PO on days 2 and 3 of chemotherapy
Mechanism of Action
Antiemetic, NK1 or Substance P (SP) antagonist
Forms Supplied
Capsule: 40 mg, 80 mg, 125 mg
Suspension (BCCH): 20 mg/mL
Comments
For prophylaxis of chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, who cannot receive dexamethasone, or who have a history of refractory nausea and vomiting with chemotherapy.
Possible adverse effects: hiccups, drowsiness, weakness, loss of appetite, headache, diarrhea or constipation, and increased liver enzymes.
Drug interactions may necessitate dose adjustment of corticosteroids and other medications metabolized by CYP 3A4.
Caution should be used if administering with ifosfamide due to risk of neurotoxicity.
Possible adverse effects: hiccups, drowsiness, weakness, loss of appetite, headache, diarrhea or constipation, and increased liver enzymes.
Drug interactions may necessitate dose adjustment of corticosteroids and other medications metabolized by CYP 3A4.
Caution should be used if administering with ifosfamide due to risk of neurotoxicity.
References
163, 349, 409
Last Edited
2021-11-08 19:04:12